• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Cardinal Health (CAH) Fully Valued As It Heads To The Wells Fargo Conference?

    Simply Wall St·09/09/2026 09:23:57
    语音播报

    Conference appearance puts Cardinal Health in focus

    Cardinal Health (CAH) is set to present at the Wells Fargo 21st Annual Healthcare Conference on 9 September 2026, giving investors fresh commentary to weigh against the stock’s recent pullback.

    Recent trading has been choppy for Cardinal Health, with the share price down 2.71% in the latest session. However, the 90 day share price return of 11.18% and 1 year total shareholder return of 60.98% point to momentum that has been building over a longer stretch.

    Spot other healthcare distributors showing similar momentum and conference-driven interest by scanning our hand-picked 82 resilient stocks with low risk scores.

    After a 61% total return over the past year and a conference spotlight this week, Cardinal Health is no longer under the radar. The question now is whether the valuation still leaves meaningful upside or already reflects the bulk of the story.

    Most Popular Narrative: 11.2% Undervalued

    Cardinal Health closed at $240.49, while the most followed narrative pegs fair value at $270.94, creating a gap that analysts try to explain through its mix of distribution and higher margin services.

    The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare, which may underpin diversified revenue growth and support margin expansion.

    Read the complete narrative.

    Curious what turns a low single digit margin distributor into a higher value story. The narrative leans heavily on mix shift, efficiency gains, and richer services layered on top of Cardinal Health's scale.

    Result: Fair Value of $270.94 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    Still, Cardinal Health faces real pressure points, including tighter drug pricing regulation and the potential loss of large customer contracts that could unsettle the current narrative.

    Find out about the key risks to this Cardinal Health narrative.

    Another View: Cardinal Health on Earnings Multiples

    Cardinal Health may look undervalued on the $270.94 fair value narrative, yet the P/E of 32.6x is higher than both the US Healthcare industry at 25.1x and the peer average at 27.1x. The fair ratio of 32.9x is very close to today’s level, which raises the question of how much room is left if sentiment cools.

    For a closer look at how this earnings multiple compares with the rest of the sector and the fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:CAH P/E Ratio as at Sep 2026
    NYSE:CAH P/E Ratio as at Sep 2026

    Next Steps

    Sentiment on Cardinal Health is mixed, with optimism and concern pulling in different directions, so move quickly and review the data on 3 key rewards and 3 important warning signs

    Looking for more investment ideas beyond Cardinal Health?

    If Cardinal Health has your attention, do not stop here. Fresh ideas often come from comparing it with other businesses that share similar strengths or offer a completely different angle.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.